Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir and Insulin Glargine

Inclusion Criteria: * Age \> 18 years and \< 80 years * Gender: female, male * Type 2 diabetes * BMI: 20.0 - 38.0 * Anti-GAD antibody negative * Fasting blood glucose \> 126 mg/dl * HbA1c 7.0 - 11.0% * Need for insulin therapy Exclusion Criteria: * Previous therapy with insulin within the last 3 months prior to inclusion into the study * Previous therapy with glitazones within the last 6 months prior to inclusion into the study * Change in therapy with lipid-lowering or anti-hypertensive agent within one month prior to inclusion into the study (a stable lipid-lowering or anti-hypertensive therapy is allowed) * Concomitant participation in other clinical trials * Type 1 diabetes * Cardiac and macrovascular disease * Malignancy including leukaemia and lymphoma within the last 5 years * Liver disease: cirrhosis or chronic active hepatitis, except fat liver * Significant renal dysfunction * other Endocrine disease * significant laboratory abnormalities * History of active substance abuse (including an average alcohol consume of \> 40g/day and drugs) within the past 2 years * Female patients: Pregnancy or childbearing potential without adequate contraception (for male patients contraception is not considered as medically important) * Present therapy with systemic steroids * Presence of psychiatric disorder or intake of anti-depressive or anti-psychotic agents with the exception of benzodiazepines and SSRIs/SNRI´s * Use of anti-obesity drugs 3 months prior or during the trial * Potentially unreliable subjects, probably non compliant subjects, and those judged by the investigator to be unsuitable for the study * Contraindications for MRI scanning such as persons with cardiac pacemaker and implants out of metal or claustrophobia * Known hypersensitivity to insulin detemir, insulin glargine or to any of the other components